

Digma Medical Ltd. – Abstract Submission

- **Investment Rational**

Digma Medical is developing a novel, medical device therapy for the treatment of metabolic disease, initially focused on type 2 diabetes. There are over 40M people with uncontrolled diabetes in the U.S./EU, despite the availability of numerous drug therapies. Digma's clinical data shows that our minimally invasive therapy is safe and sustainably lowers blood sugar levels with a one-time procedure.

- **Business Strategy**

Digma employs a traditional razor/razor blade medical device business model. Our capital equipment Console contains the hardware and software needed to safely and reliably perform our therapeutic procedure. This Console will be sold/leased to hospitals and medical centers that perform interventional endoscopy procedures. The single-use Digma Catheter will be sold for each patient/procedure, creating a high margin, recurring revenue stream.

- **Core Technology**

Digma uses a novel balloon catheter to deliver near-infrared laser energy to the small intestine, selectively ablating nerves that play a key role in regulating metabolism. We have 6 granted U.S. patents protecting our technologies. Our minimally invasive ablation technology offers the potential of a one-time treatment, reducing the burden of daily polypharmacy, costs, and side effects of current drugs.

- **Product Profile/Pipeline**

The Generation 1 Digma System received CE mark and a U.S. FDA Early Feasibility Study Investigational Device Exemption in 2021. The Company is currently completing a design optimization on the Digma Catheter before initiating the next phase of clinical studies. We have established partnerships with the leading metabolic device clinical research centers in EU and Israel to lead these studies.

- **What's Next?**

Digma is completing optimization of the Catheter in H1-22, followed by a sham-controlled clinical study in Europe and a pilot study in the U.S. These studies will further validate the safety and efficacy of our therapy. We are also pursuing feasibility data in a second metabolic indication. Digma is raising \$7M equity, with ~50% of already committed by internal investors.